Welcome to our dedicated page for Ge Healthcare Technologies SEC filings (Ticker: GEHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
GE Healthcare’s latest 10-K tops 300 pages and is packed with details on MRI backlogs, contrast-agent regulations, and high-margin service contracts—information critical yet time-consuming to dissect. If you have ever searched for “GE Healthcare insider trading Form 4 transactions” or wondered where the quarterly segment data hides, you know the challenge.
Stock Titan solves that problem. Our AI-powered summaries translate dense disclosures into plain language, flagging the numbers that matter and linking them to the exact page in the filing. Whether you need the “GE Healthcare quarterly earnings report 10-Q filing” five minutes after it hits EDGAR or an alert on a sudden “GE Healthcare 8-K material events explained,” you receive real-time updates plus expert context—no manual page flipping required.
Use our platform to:
- Track “GE Healthcare executive stock transactions Form 4” in real time and spot buying or selling trends.
- Compare R&D spend across Imaging, Ultrasound, and Pharmaceutical Diagnostics without combing through footnotes.
- Understand the “GE Healthcare annual report 10-K simplified” with AI-generated overviews, ratios, and red-flag alerts.
- Review the “GE Healthcare proxy statement executive compensation” to see how leadership pay aligns with performance.
- Download every exhibit, amendment, and “GE Healthcare Form 4 insider transactions real-time” feed in one place.
From cash-flow trends to device-approval milestones, our comprehensive coverage of all filing types—10-K, 10-Q, 8-K, Form 4, S-8, and more—gives you the clarity needed to make informed decisions. Understanding GE Healthcare SEC documents with AI has never been this straightforward.
United Therapeutics Corp. (UTHR) – Form 144 filing. Director-level insider Paul Mahon has filed to sell an additional 11,000 common shares on or about 24 Jul 2025 through Morgan Stanley Smith Barney. At the indicated market value of $3.35 million, the block equals roughly 0.024 % of the 45.1 million shares outstanding.
The filing also discloses recent insider dispositions totaling 66,000 shares over the past three months, generating $19.56 million in gross proceeds. Including the planned sale, Mahon’s cumulative dispositions would reach 77,000 shares, or ~0.17 % of shares outstanding. All shares derive from stock-option exercises paid in cash.
No company financials are provided; the document is strictly a notice required by Rule 144. While the absolute share count is modest, continued insider selling may attract investor attention. The filing confirms regulatory compliance and does not assert possession of undisclosed adverse information.
FAQ
What is the current stock price of Ge Healthcare Technologies (GEHC)?
What is the market cap of Ge Healthcare Technologies (GEHC)?
What are the core business segments of GE Healthcare Technologies Inc?
How does GE Healthcare generate recurring revenue?
What makes GE Healthcare's products unique in the medical technology market?
How does GE Healthcare address the challenges of operating in a regulated industry?
What role does advanced visualization play in GE Healthcare's offerings?
How does GE Healthcare support global healthcare providers?
How does GE Healthcare maintain operational excellence through service offerings?
What distinguishes GE Healthcare in the competitive landscape of medical technology?
